Japanese Team Starts Final-Stage Trial for iPS Drug to Treat Alzheimer's
- A new review led by a University of Nevada expert in 2025 identified 182 clinical trials assessing 138 potential Alzheimer's drugs worldwide.
- This rise of 11% from the previous year reflects growing focus on diverse treatments, including repurposed drugs originally for diabetes and multiple sclerosis.
- Researchers at the University of Virginia found that blocking the immune molecule STING may reduce Alzheimer's hallmarks, suggesting new drug targets despite potential infection risks.
- Experts highlight that recent advances, such as lecanemab and donanemab, modify disease progression and enable earlier treatment, with hope for more effective drugs within 10 to 15 years.
- Together, these developments imply that combination therapies tailored by diagnosis could improve outcomes and lead to prevention strategies for Alzheimer's in the future.
12 Articles
12 Articles
Scientists Discover Promising New Alzheimer’s Treatment
Researchers at Case Western Reserve University have developed a drug that protects the “guardian of the brain.” More than 55 million people around the world are living with dementia, most often caused by Alzheimer’s disease (AD) and other conditions that damage cells in the brain and nervous system. Despite decades of research, there is still [...]


6 things you need to know about Alzheimer’s – as drug trials bring new hope
The new review of Alzheimer’s disease in clinical trials in 2025 found 182 clinical trials assessing the impact of 138 drugs. Excitement is building as a new review shows a rise in the number of potential drugs that could treat or prevent Alzheimer’s disease. Led by an expert from the University of Nevada in the US and published in the journal Alzheimer’s & Dementia: Translational Research and Clinical Interventions, the review reveals that 182 …
Coverage Details
Bias Distribution
- 43% of the sources lean Left, 43% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage